BridgeBio Pharma, (Germany) Price Patterns
| 2CL Stock | EUR 66.46 1.42 2.18% |
Momentum 52
Impartial
Oversold | Overbought |
Quarterly Revenue Growth 43.18 |
Using BridgeBio Pharma, hype-based prediction, you can estimate the value of BridgeBio Pharma from the perspective of BridgeBio Pharma, response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in BridgeBio Pharma, to buy its stock at a price that has no basis in reality. In that case, they are not buying BridgeBio because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
BridgeBio Pharma, after-hype prediction price | EUR 65.73 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
BridgeBio |
BridgeBio Pharma, After-Hype Price Density Analysis
As far as predicting the price of BridgeBio Pharma, at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in BridgeBio Pharma, or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of BridgeBio Pharma,, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
BridgeBio Pharma, Estimiated After-Hype Price Volatility
In the context of predicting BridgeBio Pharma,'s stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on BridgeBio Pharma,'s historical news coverage. BridgeBio Pharma,'s after-hype downside and upside margins for the prediction period are 63.50 and 67.96, respectively. We have considered BridgeBio Pharma,'s daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
BridgeBio Pharma, is very steady at this time. Analysis and calculation of next after-hype price of BridgeBio Pharma, is based on 3 months time horizon.
BridgeBio Pharma, Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as BridgeBio Pharma, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BridgeBio Pharma, backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with BridgeBio Pharma,, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.37 | 2.23 | 0.73 | 0.04 | 8 Events / Month | 1 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
66.46 | 65.73 | 1.10 |
|
BridgeBio Pharma, Hype Timeline
BridgeBio Pharma, is presently traded for 66.46on Frankfurt Exchange of Germany. The entity has historical hype elasticity of -0.73, and average elasticity to hype of competition of 0.04. BridgeBio is estimated to decline in value after the next headline, with the price expected to drop to 65.73. The average volatility of media hype impact on the company price is about 113.78%. The price reduction on the next news is expected to be -1.1%, whereas the daily expected return is presently at 0.37%. The volatility of related hype on BridgeBio Pharma, is about 1903.66%, with the expected price after the next announcement by competition of 66.50. About 95.0% of the company shares are owned by institutions such as pension funds. The company recorded a loss per share of 3.57. BridgeBio Pharma, had not issued any dividends in recent years. Assuming the 90 days horizon the next estimated press release will be in about 8 days. Check out BridgeBio Pharma, Basic Forecasting Models to cross-verify your projections.BridgeBio Pharma, Related Hype Analysis
Having access to credible news sources related to BridgeBio Pharma,'s direct competition is more important than ever and may enhance your ability to predict BridgeBio Pharma,'s future price movements. Getting to know how BridgeBio Pharma,'s peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how BridgeBio Pharma, may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| RCI | Rogers Communications | 0.60 | 5 per month | 0.00 | (0.06) | 3.69 | (3.47) | 9.47 | |
| NU42 | Ribbon Communications | 0.00 | 5 per month | 0.00 | (0.17) | 3.25 | (4.26) | 10.73 | |
| SBC | Sabra Health Care | (0.07) | 6 per month | 1.52 | (0.02) | 2.41 | (2.50) | 11.42 | |
| 1ZG | Zegona Communications plc | 0.30 | 5 per month | 1.88 | 0.25 | 4.91 | (3.56) | 11.82 | |
| 3RW | VIRGIN WINES UK | 0.09 | 4 per month | 2.32 | 0.15 | 5.26 | (4.62) | 42.06 | |
| BZ7A | Bumrungrad Hospital Public | (0.1) | 6 per month | 0.00 | (0.05) | 3.30 | (3.08) | 9.04 | |
| COA1 | Comba Telecom Systems | 0.00 | 6 per month | 0.00 | (0.13) | 7.41 | (6.25) | 19.91 |
BridgeBio Pharma, Additional Predictive Modules
Most predictive techniques to examine BridgeBio price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for BridgeBio using various technical indicators. When you analyze BridgeBio charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About BridgeBio Pharma, Predictive Indicators
The successful prediction of BridgeBio Pharma, stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as BridgeBio Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of BridgeBio Pharma, based on analysis of BridgeBio Pharma, hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to BridgeBio Pharma,'s market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to BridgeBio Pharma,'s related companies.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Complementary Tools for BridgeBio Stock analysis
When running BridgeBio Pharma,'s price analysis, check to measure BridgeBio Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Pharma, is operating at the current time. Most of BridgeBio Pharma,'s value examination focuses on studying past and present price action to predict the probability of BridgeBio Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Pharma,'s price. Additionally, you may evaluate how the addition of BridgeBio Pharma, to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |